AI Insight
A large study presented at the 2026 ATS International Conference found that patients treated for chronic obstructive pulmonary disease (COPD) or pneumonia at private equity-owned hospitals experienced worse outcomes across multiple clinical measures compared to patients treated at non-private equity-owned facilities. The research suggests that private equity acquisition of hospitals may be associated with a decline in quality of care for patients with serious respiratory conditions. These findings add to a growing body of literature examining the effects of private equity ownership on healthcare quality.
Why it matters
The findings raise important public health concerns about the consequences of private equity investment in hospital systems, particularly for vulnerable patients with chronic or acute lung conditions. Policymakers and regulators may need to consider stricter oversight of hospital acquisitions to safeguard patient outcomes.
A large study presented at the 2026 ATS International Conference shows that patients treated for COPD or pneumonia experience worse outcomes across several important measures when they are treated at hospitals that have been acquired by private equity firms.
Source: Study finds outcomes for lung conditions worse at private equity-owned hospitals